Fc Engineered Anti-Human TNF Therapeutic Antibody, a CDC-Enhanced Biobetter [Lot: CB20-PZ26] (CAT#: BioBet-C026ZP) Datasheet

Target
TNF
Isotype
Whole Human Antibody
Description
CDC-enhanced Golimumabis a Fc-modified anti-TNF therapeutic biobetter. Creative Biolabs' advanced CDC-enhanced antibody platform allows for the production of Fc engineered therapeutic CDC⁺ antibodies. By mutating key amino acids of the Fc region of Golimumab, the Fc region of Golimumab exhibits a greater binding capacity to C1q, thereby achieving enhanced CDC activity.
Indication
Psoriatic arthritis aggravated
Severe Ulcerative Colitis
Active Ankylosing spondylitis
Moderate Ulcerative colitis
Moderate, active Rheumatoid arthritis
Severe, active Rheumatoid arthritis
Classification
Therapeutic antibody; biobetter
Patent
Not Available
Status
Preclinical

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced Golimumab. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
TNF
Full Name
tumor necrosis factor
Background
This gene encodes a multifunctional proinflammatory cytokine that belongs to the tumor necrosis factor (TNF) superfamily. This cytokine is mainly secreted by macrophages. It can bind to, and thus functions through its receptors TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR. This cytokine is involved in the regulation of a wide spectrum of biological processes including cell proliferation, differentiation, apoptosis, lipid metabolism, and coagulation. This cytokine has been implicated in a variety of diseases, including autoimmune diseases, insulin resistance, and cancer. Knockout studies in mice also suggested the neuroprotective function of this cytokine.
Alternative Names
DIF; TNFA; TNFSF2; TNLG1F; TNF-alpha
Gene ID
UniProt ID
Trade name
Simponi
Groups
Approved, Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Accession Number
DB06674
CAS number
476181-74-5
Antibody Isotype
Human IgG1
Description
Golimumab is a human monoclonal antibody that targets tumor necrosis factor alpha (TNF-alpha), a pro-inflammatory molecule. It is used as an immunosuppressive drug, derived from human TNFα genetically engineered mice. Golimumab is used for a variety of diseases, including moderate to severe active rheumatoid arthritis (RA), active psoriatic arthritis (PsA), and ankylosing spondylitis (AS).
Indication
Psoriatic arthritis aggravated
Severe Ulcerative Colitis
Active Ankylosing spondylitis
Moderate Ulcerative colitis
Moderate, active Rheumatoid arthritis
Severe, active Rheumatoid arthritis
Synonyms
Not Available
UNII
91X1KLU43E

Golimumab is a human monoclonal antibody that binds to soluble and transmembrane forms of TNF-α with high affinity, thereby blocking proinflammatory cascade signaling. Binding of the antibody to TNF-α prevents TNF-α from interacting with its receptor. Tumor necrosis factor-α (TNF-α) is a key pro-inflammatory cytokine involved in chronic inflammatory diseases. Its excessive activity and enhanced signaling pathways can be observed in inflammatory diseases and activate further pro-inflammatory cascades. By mediating ADCC and CDC effects, Golimumab may also lead to lysis of TNF-α1 producing cells.

Psoriatic arthritis aggravated
Severe Ulcerative Colitis
Active Ankylosing spondylitis
Moderate Ulcerative colitis
Moderate, active Rheumatoid arthritis
Severe, active Rheumatoid arthritis

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK